Skip to main content

Table 3 PGVs found in patients with full genes screened for germline variants, distributed by clinical subgroup and PAM50 molecular subtype

From: Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study

Gene

Patients

testeda

Patients with PGVs within tested

ER + /HER2 − (LN − & LN +)

HER2 + (ER − & ER +)

TNBC

Not available

All

Luminal A

Luminal B

Other PAM50 subtypes

All

HER2-enriched

Other PAM50 subtypes

All

Basal

Other PAM50 subtypes

 

BRCA1

873 (97.0%)

43/873 (4.9%)

8/538 (1.5%)

3/346 (0.9%)

3/146 (2.1%)

2/46 (4.3%)

5/127 (3.9%)

1/52 (1.9%)

4/75 (5.3%)

26/156 (16.7%)

25/139 (18%)

1/17 (5.9%)

4/52 (7.7%)

BRCA2

871 (96.8%)

36/871 (4.1%)

23/539 (4.3%)

7/345 (2%)

12/149 (8.1%)

4/45 (8.9%)

3/126 (2.4%)

1/52 (1.9%)

2/74 (2.7%)

9/154 (5.8%)

8/137 (5.8%)

1/17 (5.9%)

1/52 (1.9%)

TP53

367 (40.8%)

3/367 (0.8%)

1/202 (0.5%)

1/122 (0.8%)

0/56

0/24

1/67 (1.5%)

1/29 (3.4%)

0/38

0/83

0/79

0/4

1/15 (6.7%)

PALB2

305 (33.9%)

4/305 (1.3%)

3/171 (1.8%)

1/105 (1%)

2/45 (4.4%)

0/21

0/51

0/20

0/31

1/73 (1.4%)

1/68 (1.5%)

0/5

0/10

PTEN

283 (31.4%)

0/283

0/156

0/91

0/49

0/16

0/51

0/25

0/26

0/63

0/60

0/3

0/13

CDH1

280 (31.1%)

0/280

0/154

0/89

0/48

0/17

0/50

0/25

0/25

0/63

0/60

0/3

0/13

RAD51C

222 (24.7%)

1/222 (0.5%)

0/128

0/78

0/36

0/14

1/34 (2.9%)

1/16 (6.2%)

0/18

0/52

0/49

0/3

0/8

RAD51D

222 (24.7%)

0/222

0/128

0/78

0/36

0/14

0/34

0/16

0/18

0/52

0/49

0/3

0/8

CHEK2

186 (20.7%)

33/186 (17.7%)

23/104 (22.1%)

15/62 (24.2%)

6/29 (20.7%)

2/13 (15.4%)

6/36 (16.7%)

0/13

6/23 (26.1%)

1/36 (2.8%)

1/34 (2.9%)

0/2

3/10 (30%)

ATM

94 (10.4%)

4/94 (4.3%)

3/51 (5.9%)

1/33 (3%)

2/10 (20%)

0/8

0/17

0/4

0/13

1/24 (4.2%)

0/22

1/2 (50%)

0/2

BARD1

10 (1.1%)

1/10 (10.0%)

1/7 (14.3%)

0/3

0/1

1/3 (33.3%)

0/0

0/0

0/0

0/3

0/3

0/0

0/0

All genes

900

124/900 (13.8%)

62/560 (11.1%)

28/359 (7.8%)

25/155 (16.1%)

9/46 (19.6%)

16/128 (12.5%)

4/53 (7.5%)

12/75 (16.0%)

37/160 (23.1%)

34/143 (23.8%)

3/17 (17.6%)

9/52 (17.3%)

  1. a Patients were tested for more genes than reported in this study, but screening results are limited to genes that were of specific interest and reported back to clinicians